Ricarda Hannen

Title: The Innovative Contributions of Ricarda Hannen

Introduction

Ricarda Hannen is a prominent inventor based in Tuebingen, Germany. She has made significant strides in the field of immunotherapy, particularly in the development of peptides for cancer treatment. With a total of 10 patents to her name, Hannen's work is paving the way for advancements in medical science.

Latest Patents

One of her latest patents focuses on peptides displayed by HLA for use in immunotherapy against different types of cancers. The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 216, and a variant sequence that maintains the capacity to bind to MHC molecules and/or induce T cells that cross-react with the variant peptide, or a pharmaceutically acceptable salt thereof. This innovative approach has the potential to enhance cancer treatment options significantly.

Career Highlights

Ricarda Hannen is currently associated with Immatics Biotechnologies GmbH, where she continues to contribute to groundbreaking research in biotechnology. Her expertise and dedication to her field have established her as a key figure in the development of novel therapeutic strategies.

Collaborations

Hannen collaborates with notable colleagues, including Jens Hukelmann and Daniel Johannes Kowalewski. Their combined efforts are instrumental in advancing the research and application of immunotherapeutic peptides.

Conclusion

Ricarda Hannen's contributions to the field of immunotherapy exemplify the impact of innovative thinking in medicine. Her work not only enhances our understanding of cancer treatment but also inspires future research in biotechnology.